Nordic Pharma Launches Authorized Generic of Maxitrol
04/25/2025
Nordic Pharma announced a partnership with Harrow to launch an authorized generic of Maxitrol (Neomycin and Polymyxin B Sulfates and Dexamethasone ophthalmic suspension), for the treatment and relief of bacterial eye infections.
Maxitrol and generic equivalents had annual sales of $20.8 million in the US, according to IQVIA data, as of January 2025.
“Today marks the culmination of months of work to bring this exciting new authorized generic to the marketplace. This product is a great addition to our generic portfolio, providing patients another affordable prescription option," Thomas Sammler, VP Commercial Operations, said in a company news release.